Akari Therapeutics (AKTX) Stock Price, News & Analysis

Company Overview

Akari Therapeutics plc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel complement inhibitors for the treatment of inflammatory and immunological diseases. The company’s research centers on modulation of the complement cascade, a key component of the innate immune system, with the goal of delivering targeted therapies to patients suffering from rare and severe disorders.

Akari’s lead pipeline asset is sutimlimab, a humanized monoclonal antibody that selectively inhibits the C1s protein and is being evaluated in pivotal clinical studies for cold agglutinin disease. In addition, the company is advancing coversin, a small‐protein C5 inhibitor with potential applications in ophthalmology and hematology. These programs leverage Akari’s proprietary platform chemistry to achieve high specificity and subcutaneous dosing convenience.

Headquartered in London, United Kingdom, with research and development operations in the United States, Akari Therapeutics was founded to translate cutting-edge complement science into first-in-class medicines. The company is led by an experienced management team with deep expertise in immunology, drug development and regulatory affairs, and it collaborates with academic institutions and patient organizations to support global clinical studies and future commercialization efforts.

Key Stats

• Today's Range: $0.80 to $0.85
• 50-Day Range: $0.66 to $1.14
• 52-Week Range: $0.57 to $3.85
• Volume: 30,133 shs
• Average Volume: 274,381 shs
• Market Capitalization: $26.50 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.30
• Consensus Rating: Buy

Akari Therapeutics Stock Analysis - MarketRank™

Akari Therapeutics scored higher than 68% of companies evaluated by MarketBeat, and ranked 313th out of 948 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Buy

Consensus Rating

Akari Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Akari Therapeutics has a consensus price target of $3.30, representing about 306.2% upside from its current price of $0.81.

Amount of Analyst Coverage

Akari Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Akari Therapeutics has a P/B Ratio of 0.97. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.08% of the float of Akari Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Akari Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Akari Therapeutics has recently decreased by 68.01%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Akari Therapeutics does not currently pay a dividend.

Dividend Growth

Akari Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.08% of the float of Akari Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Akari Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Akari Therapeutics has recently decreased by 68.01%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Akari Therapeutics this week, compared to 1 article on an average week.

Search Interest

1 people have searched for AKTX on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added Akari Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Akari Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $38,660.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

38.10% of the stock of Akari Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 5.06% of the stock of Akari Therapeutics is held by institutions.

AKTX Stock Analysis - Frequently Asked Questions

How have AKTX shares performed this year?

Akari Therapeutics' stock was trading at $1.22 on January 1st, 2025. Since then, AKTX stock has decreased by 33.4% and is now trading at $0.8124.

How were Akari Therapeutics' earnings last quarter?

Akari Therapeutics PLC (NASDAQ:AKTX) announced its earnings results on Tuesday, March, 31st. The biopharmaceutical company reported ($7.80) EPS for the quarter, missing analysts' consensus estimates of ($2.80) by $5.00.

When did Akari Therapeutics' stock split?

Akari Therapeutics shares reverse split before market open on Thursday, August 17th 2023.The 1-20 reverse split was announced on Thursday, August 17th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Who are Akari Therapeutics' major shareholders?

Top institutional investors of Akari Therapeutics include Omnia Family Wealth LLC (0.19%).
View institutional ownership trends.

How do I buy shares of Akari Therapeutics?

Shares of AKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Akari Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Akari Therapeutics investors own include NVIDIA (NVDA), CymaBay Therapeutics (CBAY), Broadcom (AVGO), Novo Nordisk A/S (NVO), Adobe (ADBE), Meta Platforms (META) and GE Aerospace (GE).

Company Calendar

• Last Earnings: 3/31/2020
• Today: 9/20/2025
• Next Earnings (Estimated): 9/25/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AKTX
• CIK: 1541157
• Web: www.akaritx.com
• Phone: 442080040261
• Fax: 646-843-9352
• Employees: 9
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Akari Therapeutics: $3.30
• High Price Target: $5.00
• Low Price Target: $1.60
• Potential Upside/Downside: +306.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$19.79 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -78.03%
• Return on Assets: -31.62%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.19
• Quick Ratio: 0.19

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.84 per share
• Price / Book: 0.97

Miscellaneous

• Outstanding Shares: 32,620,000
• Free Float: 20,189,000
• Market Cap: $26.50 million
• Optionable: Not Optionable
• Beta: 0.27